86 related articles for article (PubMed ID: 12932661)
1. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
von Mehren M; Bookman M; Meropol NJ; Weiner LM; Sherman E; Li J; Knoblauch R; Parekh T; Cohen RB
Cancer Chemother Pharmacol; 2015 May; 75(5):1047-55. PubMed ID: 25791363
[TBL] [Abstract][Full Text] [Related]
3. Synthetic studies on Et-743. Assembly of the pentacyclic core and a formal total synthesis.
Fishlock D; Williams RM
J Org Chem; 2008 Dec; 73(24):9594-600. PubMed ID: 18687003
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin and its potential in the treatment of soft tissue sarcoma.
Cassier PA; Dufresne A; Blay JY; Fayette J
Ther Clin Risk Manag; 2008 Feb; 4(1):109-16. PubMed ID: 18728699
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.
Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S
Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406
[TBL] [Abstract][Full Text] [Related]
6. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
8. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
Gronchi A; Bui BN; Bonvalot S; Pilotti S; Ferrari S; Hohenberger P; Hohl RJ; Demetri GD; Le Cesne A; Lardelli P; Pérez I; Nieto A; Tercero JC; Alfaro V; Tamborini E; Blay JY
Ann Oncol; 2012 Mar; 23(3):771-776. PubMed ID: 21642514
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
Eur J Cancer; 2009 Aug; 45(12):2116-22. PubMed ID: 19419856
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK
Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
Sessa C; Perotti A; Noberasco C; De Braud F; Gallerani E; Cresta S; Zucchetti M; Viganò L; Locatelli A; Jimeno J; Feilchenfeldt JW; D'Incalci M; Capri G; Ielmini N; Gianni L
Eur J Cancer; 2009 May; 45(7):1153-1161. PubMed ID: 19114300
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
von Mehren M; Schilder RJ; Cheng JD; Temmer E; Cardoso TM; Renshaw FG; Bayever E; Zannikos P; Yuan Z; Cohen RB
Ann Oncol; 2008 Oct; 19(10):1802-9. PubMed ID: 18497430
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Messersmith WA; Jimeno A; Ettinger D; Laheru D; Brahmer J; Lansey D; Khan Y; Donehower RC; Elsayed Y; Zannikos P; Hidalgo M
Cancer Chemother Pharmacol; 2008 Dec; 63(1):181-8. PubMed ID: 18379785
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Lau L; Supko JG; Blaney S; Hershon L; Seibel N; Krailo M; Qu W; Malkin D; Jimeno J; Bernstein M; Baruchel S
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):672-7. PubMed ID: 15701855
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Le Cesne A; Blay JY; Judson I; Van Oosterom A; Verweij J; Radford J; Lorigan P; Rodenhuis S; Ray-Coquard I; Bonvalot S; Collin F; Jimeno J; Di Paola E; Van Glabbeke M; Nielsen OS
J Clin Oncol; 2005 Jan; 23(3):576-84. PubMed ID: 15659504
[TBL] [Abstract][Full Text] [Related]
18. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Garcia-Carbonero R; Supko JG; Manola J; Seiden MV; Harmon D; Ryan DP; Quigley MT; Merriam P; Canniff J; Goss G; Matulonis U; Maki RG; Lopez T; Puchalski TA; Sancho MA; Gomez J; Guzman C; Jimeno J; Demetri GD
J Clin Oncol; 2004 Apr; 22(8):1480-90. PubMed ID: 15084621
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Yovine A; Riofrio M; Blay JY; Brain E; Alexandre J; Kahatt C; Taamma A; Jimeno J; Martin C; Salhi Y; Cvitkovic E; Misset JL
J Clin Oncol; 2004 Mar; 22(5):890-9. PubMed ID: 14990645
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
